Gyorgi Keri, Of Vichem Chemie Research To Speak At Protein Kinases Mtg, May 8-9, 2014, Berlin, Deu

Top Quote Gyorgi Keri, Professor, CEO & CSO at Vichem Chemie Research Ltd. will give a presentation titled "Developing Kinase Inhibitors for Personalized Therapy," at the Protein Kinases in Drug Discovery Conference - Europe in Berlin, Germany on May 8-9, 2014 by GTC. End Quote
  • (1888PressRelease) December 16, 2013 - Gyorgi Keri is the founder of Vichem Chemie Res. Ltd. and is a Professor at Semmelweis University. He got his PhD from biochemistry in Budapest, and was post doc. at University of California, San Francisco.

    He has been working together with Professor Axel Ullrich (Max Planck Institute) for more than 25 years on developing kinase inhibitors. He was advisor and collaborative partner of SUgen Inc. from 1992 to 1999 and Axxima Pharmaceuticals from 1999 to 2005.

    He has been involved in the development of several kinase inhibitors which have been licensed for external partners. He also developed the Nested Chemical Library™ (NCL) technology, based on a knowledge based approach where focused libraries of kinase inhibitors around more than 600 scaffolds are used for hit finding and to generate pharmacophore models.

    Using the NCL™ kinase inhibitor library, Vichem has developed, and will further develop, kinase inhibitors which kill more than 95% of certain cancer cells (including cancer stem cells). The goal is to provide a personalized therapy and molecular diagnostic protocol to select who will respond to a particular cancer stem cell killing drug.

    The Protein Kinases in Drug Discovery Conference - Europe, to be held on May 8-9, 2014, in Berlin, Germany, will be a premier conference that will host an exciting group of professionals from the academic, biotech, pharmaceutical, and business communities, and will focus on drug discovery aspects within the protein kinases field. A balance of both academic and industry experts will facilitate discussion on validation of novel drug targets, current progress in drug design, kinases inhibitor development, and preclinical models and clinical development.

    For more information, please visit

  • FB Icon Twitter Icon In-Icon
Contact Information